Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 1.00 |
| ▸ | FXR2 | P51116 | 1/20 | 0.86 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17087849 | 1.00 | NR1H4 (1.00) | NR1H4FXR2HSD17B13 | |
| SCHEMBL17087853 | 1.00 | NR1H4 (1.00) | NR1H4FXR2HSD17B13 | |
| SCHEMBL12168956 | 1.00 | NR1H4 (1.00) | NR1H4FXR2HSD17B13 | |
| SCHEMBL29880955 | 1.00 | NR1H4 (1.00) | NR1H4FXR2HSD17B13 | |
| SCHEMBL17087847 | 1.00 | NR1H4 (1.00) | NR1H4FXR2HSD17B13 | |
| SCHEMBL12879039 | 1.00 | NR1H4 (1.00) | NR1H4FXR2HSD17B13 | |
| SCHEMBL1164201 | 0.94 | NR1H4 (0.90) | NR1H4FXR2HSD17B13 | |
| SCHEMBL29880621 | 0.94 | NR1H4 (0.90) | NR1H4FXR2HSD17B13 | |
| SCHEMBL24585950 | 0.94 | NR1H4 (0.89) | NR1H4FXR2HSD17B13 | |
| SCHEMBL12808764 | 0.93 | NR1H4 (0.87) | NR1H4FXR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952042-B2 | FXR (NR1H4) binding and activity modulating compounds | PHENEX PHARMACEUTICALS AG (DE) | 2015-02-10 | — | — | US | claimed |
| EP-2467366-B1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2014-11-12 | — | — | EP | claimed |
| WO-2013037482-A1 | FARNESOID X RECEPTOR AGONISTS FOR CANCER TREATMENT AND PREVENTION | PHENEX PHARMACEUTICALS AG (DE) | 2013-03-21 | — | — | WO | claimed |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-09-13 | — | — | US | claimed |
| EP-2467366-A1 | NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS | Phenex Pharmaceuticals AG (DE) | 2012-06-27 | — | — | EP | claimed |
| EP-2289883-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | Phenex Pharmaceuticals AG (DE) | 2011-03-02 | — | — | EP | claimed |
| WO-2011020615-A1 | NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2011-02-24 | — | — | WO | claimed |
| EP-4400503-A2 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-110404073-B | Methods and pharmaceutical compositions for treating hepatitis B virus infection | 国家医疗保健研究所 | 2022-08-16 | — | — | CN | disclosed |
| EP-3043865-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | INST NAT SANTE RECH MED (FR) | 2020-11-04 | — | — | EP | disclosed |
| EP-3711762-A1 | A FARNESOID X RECEPTOR AGONSITS FORUSE AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-09-23 | — | — | EP | disclosed |
| US-20190142814-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | PHENEX PHARMACEUTICALS AG (DE) | 2019-05-16 | — | — | US | disclosed |
| US-10220027-B2 | FXR (NR1H4) binding and activity modulating compounds | GILEAD SCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| EP-2545964-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | Phenex Pharmaceuticals AG (DE) | 2013-01-16 | — | — | EP | disclosed |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-09-13 | — | — | US | disclosed |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-09-13 | — | — | US | disclosed |
| EP-2467366-A1 | NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS | Phenex Pharmaceuticals AG (DE) | 2012-06-27 | — | — | EP | disclosed |
| EP-2289883-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | Phenex Pharmaceuticals AG (DE) | 2011-03-02 | — | — | EP | disclosed |
| EP-2289883-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | Phenex Pharmaceuticals AG (DE) | 2011-03-02 | — | — | EP | disclosed |
| WO-2011020615-A1 | NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10220027-B2 | FXR (NR1H4) binding and activity modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885FXR2 5/4885HSD17B13 360/4885 |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885FXR2 5/4885HSD17B13 504/4885 |
| US-20190142814-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885FXR2 5/4885HSD17B13 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.